1. Home
  2. NSPR vs ACET Comparison

NSPR vs ACET Comparison

Compare NSPR & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InspireMD Inc.

NSPR

InspireMD Inc.

HOLD

Current Price

$1.95

Market Cap

81.8M

Sector

Health Care

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$0.55

Market Cap

93.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NSPR
ACET
Founded
2005
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
81.8M
93.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NSPR
ACET
Price
$1.95
$0.55
Analyst Decision
Strong Buy
Buy
Analyst Count
2
4
Target Price
$4.50
$8.50
AVG Volume (30 Days)
112.9K
1.9M
Earning Date
11-04-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$7,779,000.00
N/A
Revenue This Year
$22.76
N/A
Revenue Next Year
$75.45
N/A
P/E Ratio
N/A
N/A
Revenue Growth
14.04
N/A
52 Week Low
$1.59
$0.45
52 Week High
$3.80
$1.11

Technical Indicators

Market Signals
Indicator
NSPR
ACET
Relative Strength Index (RSI) 46.66 38.25
Support Level $1.74 $0.50
Resistance Level $1.93 $0.57
Average True Range (ATR) 0.15 0.05
MACD 0.00 0.00
Stochastic Oscillator 51.14 26.56

Price Performance

Historical Comparison
NSPR
ACET

About NSPR InspireMD Inc.

InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: